• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    CalAmp Reports First Quarter Fiscal Year 2024 Financial Results

    7/10/23 4:05:03 PM ET
    $CAMP
    Get the next $CAMP alert in real time by email

    Gross Margin increases 280 basis points and Adjusted EBITDA remained strong in the quarter at $6.0 million

    The Company's Board of Directors has decided to explore strategic alternatives

    IRVINE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its first quarter of fiscal year 2024 ended May 31, 2023.

    First Quarter Fiscal Year 2024 Financial Overview

    • Total revenue was $70.9 million in the quarter, a $7.6 million decline sequentially and $6.2 million increase year over year.
    • Software and Subscription Services (S&SS) revenue was $45.0 million in the quarter, down $6.4 million sequentially and up $5.4 million year over year.
    • Telematics Products revenue was $25.9 million, including a strong quarter from a large Industrial customer. This represented a $1.2 million decline sequentially and $0.8 million increase year over year.
    • Recurring Application Subscription revenues were $19.2 million, representing a $0.1 million sequential growth, and $1.1 million decline year over year.
    • Quarter End Remaining Performance Obligations (RPO) of $217.5 million, down sequentially by $20 million, driven by a few customers making contract modifications.
    • Telematics Products backlog was at $20 million, down sequentially by $9 million, reflecting improved supply.
    • Gross margin in the quarter increased 280 basis points sequentially to 38.2% as product mix shifted to higher margins.
    • Adjusted EBITDA was flat sequentially at $6.0 million in the quarter, or approximately 9% of revenue, driven by improved gross margins and cost control.
    • GAAP net loss from continuing operations was $4.0 million, or a loss of $0.11 per share, a sequential improvement from loss of $8 million or $0.22 per share.
    • Ended the quarter with $35.0 million in cash and cash equivalents; have $35.6 million of undrawn line availability subject to customary covenant tests.

    Jeff Gardner, CalAmp's CEO, commented: "First quarter revenues came in at $70.9 million, up 10% year over year, and we recognized another sequential increase in gross margin and cost efficiencies from our continued expense management efforts which all contributed to a solid first quarter Adjusted EBITDA of $6.0 million. Strategically, we have converted the installed base to a subscription model, focused the sales organization on selling full stack solutions, stood up a customer success team to drive retention and upselling, and restructured the business to improve cash flow and profitability. With the recent release of exciting new products—such as our next generation Video Dash Camera—CalAmp is positioned to drive high-margin recurring revenue growth from direct fleet customers."

    "Over the past few years, CalAmp has been executing a strategy to create shareholder value as an independent company. In the past weeks, we have received unsolicited inbound inquiries, as a result of which the Board of Directors has engaged advisors and formed a special committee to help us explore all strategic alternatives."

    Business and Recent Highlights

    • Completed the active conversion effort of transferring legacy device customers to subscription models.
    • Signed multiple new enterprise fleet customers, including a deal with R&L Carriers that added ~18,000 subscribers post FY24 Q1 close.
    • Released the next gen CalAmp Vision solution, which includes a dual facing dash cam and AI-based software; have already sold units and will continue to execute towards closing additional opportunities from a growing sales pipeline.

    Summary Financial Information From Continuing Operations:

    (In thousands except per share amounts)

      Three Months Ended 
      May 31, 
    Description 2023  2022 
    Revenues:      
    Software & Subscription Services (S&SS) $44,952  $39,557 
    Telematics Products  25,939   25,169 
      $70,891  $64,726 
    Gross profit  27,061   25,647 
           
    Gross margin  38%  40%
           
    Net loss $(4,032) $(12,173)
    Net loss per diluted share $(0.11) $(0.34)
    Non-GAAP measures:      
    Adjusted EBITDA $6,045  $1,856 
    Adjusted EBITDA margin  9%  3%



      May 31,  February 28, 
    Description 2023  2023 
    Cash and cash equivalents $34,960  $41,928 
    Working capital  68,748   68,295 
    Deferred revenue  35,291   36,552 
    Total debt (carrying value)  227,966   228,121 



      May 31, 
    S&SS Supplemental Information: 2023  2022 
    Remaining performance obligations $217,490  $215,000 
    Subscribers  1,687   1,195 



     Three Months Ended 
     May 31, 2023  May 31, 2022  Feb 28, 2023 
    Revenue by type of goods and services:        
    Telematics devices and accessories$46,291  $39,395  $50,461 
    Rental income and other services$5,434   4,270  $8,623 
    Recurring application subscriptions (1)$19,166   21,061  $19,422 
    Total$70,891  $64,726  $78,506 
             
    Recurring application subscriptions, excluding Automotive Vehicle Finance Business (1)$19,166  $20,280  $19,079 
                

    (1)   Recurring application subscriptions includes $0.0 million, $0.8 million, and $0.3 million during the three months ended May 31, 2023, May 31, 2022, and February 28, 2023, respectively, attributable to the auto vehicle finance business which has been completely wound down.

    Second Quarter Fiscal Year 2024 Business Outlook

    We expect FY24 Q2 revenues to range between $67 and $73 million with adjusted EBITDA between $5 and $9 million.

    A reconciliation of non-GAAP guidance financial measures to corresponding GAAP guidance financial measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty and potential variability of expenses, such as stock-based compensation expense-related charges, that may be incurred in the future and cannot be reasonably determined or predicted at this time. It is important to note that these factors could be material to our results of operations computed in accordance with GAAP.

    Conference Call and Webcast

    CalAmp is hosting a conference call for analysts and investors to discuss its first quarter fiscal year 2024 results at 2:00 p.m. Pacific Time today. Participants can listen in via webcast by visiting the Investor Relations section of its website at www.calamp.com. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A replay of the webcast will be available for 90 days after the call. The conference call can also be accessed by dialing 833-470-1428 (+1-404-975-4839 for international callers) and using the Conference ID #597090. Following the call, an audio replay will also be available by calling 866-813-9403 or 1-929-458-6194 and entering the Replay ID # 915253. The audio replay will be available through July 17, 2023.

    About CalAmp

    CalAmp (NASDAQ:CAMP) provides flexible solutions to help organizations worldwide monitor, track and protect their vital assets. Our unique combination of software, devices, and platform enables over 14,000 commercial and government organizations worldwide to increase efficiency, safety and transparency while accommodating the unique ways they do business. With over 10 million active edge devices and 275+ issued or pending patents, CalAmp is the telematics leader organizations turn to for innovation and dependability. For more information, visit calamp.com, or LinkedIn, Twitter, YouTube or CalAmp Blog.

    Forward-Looking Statements

    This announcement contains forward-looking statements (including within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and Section 27A of the U.S. Securities Act of 1933, as amended) concerning CalAmp. These statements include, but are not limited to, statements that address our expected future business and financial performance and statements about (i) our plans, objectives and intentions with respect to future operations, services and products, (ii) our competitive position and opportunities, (iii) our comprehensive review of strategic alternatives focused on enhancing shareholder value, and (iv) other statements identified by words such as such as "may", "will", "expect", "intend", "plan", "potential", "believe", "seek", "could", "estimate", "judgment", "targeting", "should", "anticipate", "predict", "project", "aim", "goal", and similar words, phrases or expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as assumptions made by, and information currently available to, management, current market trends and market conditions, and involve risks and uncertainties, many of which are outside of our control, and which may cause actual results to differ materially from those contained in forward-looking statements. Accordingly, you should not place undue reliance on such statements. Particular uncertainties that could materially affect future results include any risks associated with global economic conditions and concerns; the outcome of our comprehensive review of strategic alternatives, including the availability of any strategic alternatives that are worthwhile to pursue; the effects of global outbreaks of pandemics or contagious diseases or fear of such outbreaks, such as the recent coronavirus (COVID-19) pandemic; global component shortages due to supply chain constraints caused by the COVID-19 pandemic; disruptions in sales, operations, relationships with customers, suppliers, employees; our ability to successfully and timely accomplish our transformation to a SaaS solutions provider; our transition out of the automotive vehicle financing business; competitive pressures; pricing declines; demand for our telematics products; rates of growth in our target markets; prolonged disruptions of our contract manufacturers' facilities or other significant operations; force majeure or force-majeure-like events at our contract manufacturers' facilities including component shortages; the ongoing diversification of our global supply chain; our dependence on outsourced service providers for certain key business services and their ability to execute to our requirements; our ability to improve gross margin; cost-containment measures; legislative, trade, tariff, and regulatory actions; integration, unexpected charges or expenses in connection with acquisitions; the impact of legal proceedings and compliance risks; the impact on our business and reputation from information technology system failures, network disruptions, cyber-attacks, or losses or unauthorized access to, or release of, confidential information; the ability of the Company to comply with laws and regulations regarding data protection; our ability to protect our intellectual property and the unpredictability of any associated litigation expenses; any expenses or reputational damage associated with resolving customer product and warranty and indemnification claims; our ability to sell to new types of customers and to keep pace with technological advances; market acceptance of the end products into which our products are designed; and other events and trends on a national, regional and global scale, including those of a political, economic, business, competitive, and regulatory nature. More information on these risks and other potential factors that could affect our financial results is included in our filings with the U.S. Securities and Exchange Commission ("SEC"), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings, which you may obtain for free at the SEC's website at http://www.sec.gov. We undertake no intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise, which speak as of their respective dates except as required by law.

    Non-GAAP Financial Measures

    "GAAP" refers to financial information presented in accordance with U.S. Generally Accepted Accounting Principles. This announcement includes non-GAAP financial measures, as defined in Regulation G promulgated by the SEC. We believe that our presentation of non-GAAP financial measures provides useful supplementary information to investors. These non-GAAP financial measures are provided in addition to, and not as a substitute for measures of financial performance prepared in accordance with GAAP.

    In this announcement, we report the non-GAAP financial measures of Adjusted EBITDA (earnings before investment income, interest expense, taxes, depreciation, amortization, stock-based compensation, acquisition and integration expenses, non-cash costs and expenses arising from purchase accounting adjustments, litigation and legal expenses, impairment losses and certain other adjustments as detailed in the accompanying non-GAAP reconciliation), and Adjusted EBITDA margin. We use these non-GAAP financial measures to provide investors with additional information about our financial performance and future prospects of our core business activities. Internally, these non-GAAP measures are significant measures used by management for purposes of evaluating our core operating performance, establishing internal budgets, calculating return on investment for development programs and growth initiatives, comparing performance with internal forecasts and targeted business models, strategic planning, evaluating and valuing potential acquisition candidates and how their operations compare to our operations, and benchmarking performance externally against our competitors. We believe this non-GAAP financial information provides additional insight into our ongoing performance and have therefore chosen to provide this information to investors to help them evaluate our results of ongoing operations and enable additional period-to-period comparisons. The presentation of these and other similar items in our non-GAAP financial results should not be interpreted as implying that these items are non-recurring, infrequent, or unusual.

    CalAmp, LoJack, TRACKER, Here Comes The Bus, Bus Guardian, iOn Vision, CrashBoxx and associated logos are among the trademarks of CalAmp and/or its affiliates in the United States, certain other countries and/or the EU. Spireon acquired the LoJack® U.S. Stolen Vehicle Recovery (SVR) business from CalAmp and holds an exclusive license to the LoJack mark in the United States and Canada. Any other trademarks or trade names mentioned are the property of their respective owners.

    AT CALAMP:AT CALAMP:
    Jikun KimLogan Lucas
    SVP & CFOCorporate Strategy
    [email protected][email protected]



    CALAMP CORP.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (Amounts in thousands, except per share amounts)

    (Unaudited)

     Three Months Ended 
     May 31, 
      2023   2022 
            
    Revenues$70,891  $64,726 
    Cost of revenues 43,830  $39,079 
    Gross profit 27,061   25,647 
    Operating expenses:       
    Research and development 5,842  $7,000 
    Selling and marketing 11,023  $11,478 
    General and administrative 11,354  $15,162 
    Intangible asset amortization 1,222  $1,342 
    Total operating expenses 29,441   34,982 
    Operating loss (2,380)  (9,335)
    Non-operating income (expense):       
    Investment income 207  $(114)
    Interest expense (1,678) $(1,533)
    Other expense, net (129) $(942)
    Total non-operating expenses (1,600)  (2,589)
    Loss from operations before income taxes (3,980)  (11,924)
    Income tax provision (52) $(249)
    Net loss$(4,032) $(12,173)
    Loss per share - continuing operations:       
    Basic$(0.11) $(0.34)
    Diluted$(0.11) $(0.34)
    Earnings per share - discontinued operations:       
    Basic$-  $- 
    Diluted$-  $- 
    Shares used in computing earnings (loss) per share:       
    Basic 36,632   35,723 
    Diluted 36,632   35,723 
            



    CALAMP CORP.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Amounts in thousands)

    (Unaudited)

      May 31,  February 28, 
      2023  2023 
    Assets       
             
    Current assets:        
    Cash and cash equivalents $34,960  $41,928 
    Accounts receivable, net  85,033   82,946 
    Inventories  24,336   23,902 
    Prepaid expenses and other current assets  23,848   26,019 
    Total current assets  168,177   174,795 
             
    Property and equipment, net  31,526   32,832 
    Operating lease right-of-use assets  11,632   12,293 
    Deferred income tax assets  3,624   3,275 
    Goodwill  94,708   94,214 
    Other intangible assets, net  25,695   26,633 
    Other assets  36,872   36,078 
    Total assets $372,234  $380,120 
             
    Liabilities and Stockholders' Equity        
             
    Current liabilities:        
    Current portion of long-term debt $276  $705 
    Accounts payable  47,904   52,716 
    Accrued payroll and employee benefits  11,583   11,766 
    Deferred revenue  22,143   25,448 
    Other current liabilities  17,523   15,865 
    Total current liabilities  99,429   106,500 
             
    Long-term debt, net of current portion  227,690   227,416 
    Operating lease liabilities  11,277   12,314 
    Other non-current liabilities  21,394   19,583 
    Total liabilities  359,790   365,813 
    Stockholders' equity:        
    Common stock  375   374 
    Additional paid-in capital  186,592   184,672 
    Accumulated deficit  (172,848)  (168,816)
    Accumulated other comprehensive loss  (1,675)  (1,923)
    Total stockholders' equity  12,444   14,307 
    Total liabilities and stockholders' equity $372,234  $380,120 
             



    CALAMP CORP.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Amounts in thousands)

    (Unaudited)

     Fiscal Year Ended 
     May 31, 
     2023

      2022

     
    CASH FLOWS FROM OPERATING ACTIVITIES:       
    Net loss$(4,032) $(12,173)
            
    Depreciation expense 4,328   4,156 
    Intangible asset amortization 1,222   1,342 
    Stock-based compensation 2,178   2,960 
    Amortization of debt issuance costs and discount 281   304 
    Non-cash operating lease cost 842   893 
    Revenue assigned to factors (436)  (784)
    Deferred tax assets, net (304)  109 
    Other 22   - 
    Changes in operating assets and liabilities of continuing operations (7,081)  (12,357)
    NET CASH USED IN OPERATING ACTIVITIES (2,980)  (15,550)
            
    CASH FLOWS FROM INVESTING ACTIVITIES:       
    Capital expenditures (1,958)  (3,630)
    NET CASH USED IN INVESTING ACTIVITIES (1,958)  (3,630)
            
    CASH FLOWS FROM FINANCING ACTIVITIES:       
    Taxes paid related to net share settlement of vested equity awards (257)  (425)
    NET CASH USED IN FINANCING ACTIVITIES (257)  (425)
            
    EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS (1,773)  (576)
    Net change in cash and cash equivalents (6,968)  (20,181)
    Cash and cash equivalents at beginning of year 41,928   79,221 
    Cash and cash equivalents at end of year$34,960  $59,040 
            



    CALAMP CORP.

    RECONCILIATION OF NON-GAAP MEASURES TO GAAP

    (Unaudited)

    GAAP refers to financial information presented in accordance with U.S. Generally Accepted Accounting Principles. This announcement includes non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission. We believe that our presentation of non-GAAP financial measures provides useful supplementary information to investors. The presentation of non-GAAP financial measures is not meant to be considered in isolation from or as a substitute for results prepared in accordance with GAAP.

    In this announcement, we report the non-GAAP financial measures of Adjusted EBITDA (earnings before investment income, interest expense, taxes, depreciation, amortization, stock-based compensation and other adjustments as identified below), and Adjusted EBITDA margin. We use these non-GAAP financial measures to provide investors with an overall understanding of the financial performance and future prospects of our core business activities. Specifically, we believe that the use of these non-GAAP measures facilitates the comparison of results of core business operations between current and past periods.

    The reconciliation of GAAP-basis net loss to Adjusted EBITDA and the calculation of Adjusted EBITDA margin are as follows (dollars in thousands):

     Three Months Ended 
     May 31, 
     2023  2022 
            
    GAAP basis net loss$(4,032) $(12,173)
            
    Investment (income) loss (207)  114 
    Interest expense 1,678   1,533 
    Income tax provision 52   249 
    Depreciation and amortization 5,550   5,498 
    Stock-based compensation 2,178   2,960 
    Litigation and non-recurring legal expenses 175   3,131 
    Restructuring -   - 
    Costs incurred in transition of LoJack North America business to acquiror (a) 36   752 
    Other 615   (208)
    Adjusted EBITDA$6,045  $1,856 
            
    Revenues$70,891  $64,726 
            
    Adjusted EBITDA margin 9%  3%
            

    (a)   Costs incurred in transition of business to acquiror are attributable to the wind-down and transfer of the LoJack North America business to Spireon.



    Primary Logo

    Get the next $CAMP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CAMP

    DatePrice TargetRatingAnalyst
    5/27/2025$8.00Outperform
    Wedbush
    11/5/2024Outperform
    William Blair
    11/5/2024$18.00Overweight
    Piper Sandler
    11/5/2024$23.00Overweight
    JP Morgan
    8/16/2022$8.00 → $10.00Hold → Buy
    Craig Hallum
    12/22/2021$15.00 → $14.00Buy
    Canaccord Genuity
    12/22/2021$14.00 → $10.00Buy → Hold
    Craig-Hallum
    9/24/2021$16.00 → $14.00Buy
    Craig Hallum
    More analyst ratings

    $CAMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Nashat Amir

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      6/27/25 4:02:31 PM ET
      $CAMP
    • SEC Form 4 filed by Director Young Richard A

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      6/27/25 4:03:11 PM ET
      $CAMP
    • SEC Form 4 filed by Director Holtzman Steven H

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      6/27/25 4:02:41 PM ET
      $CAMP

    $CAMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Large owner Polaris Management Co. Vii, L.L.C. converted options into 1,715,972 shares and bought $9,999,990 worth of shares (909,090 units at $11.00) (SEC Form 4)

      4/A - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/22/24 5:31:39 PM ET
      $CAMP
    • Large owner Northpond Ventures Ii Gp, Llc converted options into 1,474,608 shares and bought $8,399,996 worth of shares (763,636 units at $11.00) (SEC Form 4)

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/17/24 6:34:47 PM ET
      $CAMP
    • Large owner Ah Equity Partners Bio I, L.L.C. converted options into 1,398,067 shares and bought $7,999,992 worth of shares (727,272 units at $11.00) (SEC Form 4)

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/17/24 5:05:20 PM ET
      $CAMP

    $CAMP
    SEC Filings

    See more
    • CAMP4 Therapeutics Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

      6/13/25 4:03:08 PM ET
      $CAMP
    • CAMP4 Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

      5/16/25 6:28:22 AM ET
      $CAMP
    • SEC Form SCHEDULE 13G filed by CAMP4 Therapeutics Corporation

      SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      5/14/25 1:45:31 PM ET
      $CAMP

    $CAMP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sequans Appoints Jason W. Cohenour to Board of Directors

      Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading innovator in cellular IoT semiconductor solutions, today announced the appointment of Jason W. Cohenour to its Board of Directors.Mr. Cohenour brings more than 30 years of executive leadership experience across sales, operations, and international mergers and acquisitions. He served as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018, where he led a strategic transformation that created a global leader in the Internet of Things and drove company revenues to nearly USD $800 million. Prior to his CEO role, he held several senior positions at Sierra

      6/30/25 8:00:00 AM ET
      $CAMP
      $LTRX
      $RFIL
      $SQNS
      Computer Communications Equipment
      Telecommunications
      Electrical Products
      Technology
    • CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

      Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes CMP-SYNGAP-01 administration led to a significant increase in SYNGAP1 protein levels in relevant brain regions in non-human primates (NHPs) Patient safety and pharmacokinetic data from single ascending dose (SAD) cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers highlighted CAMBRIDGE, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting th

      5/16/25 6:00:00 AM ET
      $CAMP
    • CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

      Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotesNominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025American Society of Cell and Gene Therapy (ASGCT) oral presentations to highlight meaningful increase in SYNGAP1 protein, driven by lead ASO candidate, CMP-SYNGAP-01, in non-human primates (NHP) and review interim SAD data from the Phase 1 trial of CMP-CPS-0

      5/13/25 4:05:11 PM ET
      $CAMP

    $CAMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on CAMP4 Therapeutics with a new price target

      Wedbush initiated coverage of CAMP4 Therapeutics with a rating of Outperform and set a new price target of $8.00

      5/27/25 9:09:57 AM ET
      $CAMP
    • William Blair initiated coverage on CAMP4 Therapeutics

      William Blair initiated coverage of CAMP4 Therapeutics with a rating of Outperform

      11/5/24 7:23:37 AM ET
      $CAMP
    • Piper Sandler initiated coverage on CAMP4 Therapeutics with a new price target

      Piper Sandler initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $18.00

      11/5/24 6:14:46 AM ET
      $CAMP

    $CAMP
    Leadership Updates

    Live Leadership Updates

    See more
    • Sequans Appoints Jason W. Cohenour to Board of Directors

      Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading innovator in cellular IoT semiconductor solutions, today announced the appointment of Jason W. Cohenour to its Board of Directors.Mr. Cohenour brings more than 30 years of executive leadership experience across sales, operations, and international mergers and acquisitions. He served as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018, where he led a strategic transformation that created a global leader in the Internet of Things and drove company revenues to nearly USD $800 million. Prior to his CEO role, he held several senior positions at Sierra

      6/30/25 8:00:00 AM ET
      $CAMP
      $LTRX
      $RFIL
      $SQNS
      Computer Communications Equipment
      Telecommunications
      Electrical Products
      Technology
    • CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

      With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William

      3/18/25 8:00:00 AM ET
      $CAMP
    • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

      CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

      12/10/24 8:00:00 AM ET
      $CAMP
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAMP
    Financials

    Live finance-specific insights

    See more
    • CalAmp Reports Third Quarter Fiscal Year 2024 Financial Results

      IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview    Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5

      1/9/24 4:30:00 PM ET
      $CAMP
    • CalAmp Announces Date for Fiscal 2024 Third Quarter Earnings Conference Call

      IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla

      12/26/23 4:30:00 PM ET
      $CAMP
    • CalAmp Announces Completion of Strategic Financing with Lynrock Lake

      IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add

      12/18/23 4:31:00 PM ET
      $CAMP

    $CAMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

      SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 6:49:57 PM ET
      $CAMP
    • SEC Form SC 13D filed by CAMP4 Therapeutics Corporation

      SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 5:50:56 PM ET
      $CAMP
    • SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

      SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 4:19:08 PM ET
      $CAMP